At the time of the original presentation of data from the CHAARTED trial, the median follow-up for patients enrolled in this trial was 28.9 months. We now have data from the same 790 patients followed for a median of 53.7 months. … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: CHAARTED, follow-up. long-term, hormone-sensitive, metastatic | 10 Comments »
For many years now, people have asked whether specific PSA levels after initiation of androgen deprivation therapy (ADT, also known as “hormone therapy”) have significant predictive impact on long-term survival. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, CHAARTED, deprivation, hormone-sensitive, metastatic, PSA, survival | 7 Comments »
So the discussion about how to use the data from the CHAARTED, STAMPEDE, and LATITUDE trials in the initial treatment of men with node-positive and metastatic hormone-sensitive and castration-resistant prostate cancer continues to be an issue of intense discussion among urologic and medical oncologists. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: CHAARTED, hormone-sensitive, latitude, metastatic, mHSPC, nmHSPC, non-metastatic, STAMPEDE | 1 Comment »
As regular readers will be aware, the data from the CHAARTED trial were the first to show that combining androgen deprivation (ADT) with docetaxel chemotherapy has a significant, life-extending benefit in at least some men newly diagnosed with metastatic prostate cancer. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, CHAARTED, deprivation, docetaxel, quality of life | 1 Comment »
The final results of the CHAARTED trial, recommending early treatment with the combination of androgen deprivation therapy (ADT) and chemotherapy, at least in men with extensive metastasis at diagnosis, have just been published this week by Sweeney et al. in The New England Journal of Medicine (NEJM). … READ MORE …
Filed under: Diagnosis, Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen, CHAARTED, chemotherapy, combination, deprivation, Diagnosis, metastatic | 8 Comments »
In the October 15 issue of Oncology differing authors provide differing perspectives on the interpretation of the results of the CHAARTED trial reported by Sweeney et al. at the annual meeting of the American Society for Clinical Oncology earlier this year. … READ MORE …
Filed under: Living with Prostate Cancer, Management, Treatment | Tagged: ADT, androgen deprivation, CHAARTED, docetaxel, metastatic, treatment-naive | 1 Comment »
News and information provided on this site should not be used for diagnosing or treating any health problem or disease.
The “New” Prostate Cancer InfoLink is intended for informational purposes only. It is not engaged in rendering medical advice or professional services and is not a substitute for professional care. If you have or suspect you may have a health problem, please consult your healthcare provider.
Blog at WordPress.com. WP Designer.
THE "NEW" PROSTATE CANCER INFOLINK